生物制剂时代类风湿关节炎全关节置换术发生率是否下降?基于人群的队列研究
该研究基于加拿大不列颠哥伦比亚省人群队列,比较生物制剂DMARDs(bDMARDs)应用前后诊断的RA与OA患者8年全髋/全膝关节置换术(THA/TKA)发生率趋势。结果显示,bDMARDs后诊断的RA患者THA/TKA发生率随时间下降,而OA患者仍上升;bDMARDs引入后5年诊断的RA队列8年THA和TKA发生率分别较预期低26.9%和12.6%。
要点
- bDMARDs应用后诊断的RA患者8年THA/TKA发生率随时间下降,OA患者仍上升。
- bDMARDs引入后5年诊断的RA队列8年THA和TKA发生率分别较预期低26.9%和12.6%。
- RA与OA的THA/TKA发生率趋势差异显著,支持生物制剂时代RA治疗改善。
核心结论
- bDMARDs引入后诊断为RA的患者THA/TKA发生率显著降低,而OA患者未降低,反映生物制剂时代RA治疗显著改善。
主要发现
- bDMARDs前诊断的RA和OA队列8年THA/TKA发生率均随时间增加;bDMARDs后诊断的RA队列发生率随时间下降,而OA队列继续增加。
- RA的THA发生率bDMARDs后与bDMARDs前趋势差异为-0.49(P=0.002),TKA为-0.36(P=0.003);OA相应差异分别为+0.40(P=0.006)和+0.54(P<0.001)。
- bDMARDs引入后5年诊断的RA队列8年THA和TKA发生率分别较预期低26.9%和12.6%;OA相应发生率分别高11.7%和16.6%。
临床怎么用
- 在RA管理中,bDMARDs的应用与THA/TKA发生率降低相关,支持积极控制疾病活动以降低关节置换需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether the introduction of biological DMARDs (bDMARDs) was associated with reduced incidences of total hip and knee arthroplasty (THA/TKA) among patients with RA compared with OA. METHODS: Using a population-based cohort in British Columbia, Canada, RA and OA patients diagnosed between 1995 and 2007 were divided into semi-annual cohorts according to diagnosis date. For each cohort, we calculated 8-year incidence rates of THA and TKA. We compared levels and trends of THA/TKA incidence in RA/OA patients diagnosed during pre-bDMARDs (1995-2001) and post-bDMARDs (2003-2007) periods using interrupted time-series analysis, adjusting for baseline characteristics. Adjusted 8-year total joint arthroplasty incidence estimated for RA/OA cohorts diagnosed five years after bDMARDs introduction were compared with expected rates assuming no bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. RESULTS: We identified 60 227 RA and 288 260 OA incident cases. For cohorts diagnosed pre-bDMARDs, 8-year THA/TKA incidence rates increased over time in both RA and OA. For cohorts diagnosed post-bDMARDs, these rates decreased over time in RA but continued to increase for OA. For RA, differences between the post- and pre-bDMARDs secular trends in incidence rates were -0.49 (P = 0.002) for THA and -0.36 (P = 0.003) for TKA, compared with +0.40 (P = 0.006) and +0.54 (P < 0.001), respectively, for OA. For RA cohorts diagnosed five years after bDMARDs introduction, 8-year incidences were 26.9% and 12.6% lower for THA and TKA, respectively, than expected rates. In contrast, corresponding rates in OA were higher by 11.7% and 16.6%, respectively. CONCLUSION: Arthritis onset after bDMARDs introduction is associated with a significant reduction in THA/TKA incidence in RA, but not in OA. The reduction reflects a significant improvement in RA treatment during the biological era.
引用
- Zhou VY, Lacaille D, Lu N, et al. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study. Rheumatology (Oxford). 2022. PMID: 34373899. doi:10.1093/rheumatology/keab643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。